Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer

We conducted a preoperative window study of metformin in endometrial cancer (EC) patients and evaluated its antiproliferative, molecular and metabolic effects. Twenty obese women with endometrioid EC were treated with metformin (850 mg) daily for up to 4 weeks prior to surgical staging. Expression o...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuler, Kevin M, Rambally, Brooke S, DiFurio, Megan J, Sampey, Brante P, Gehrig, Paola A, Makowski, Liza, Bae-Jump, Victoria L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329001/
https://www.ncbi.nlm.nih.gov/pubmed/25417601
http://dx.doi.org/10.1002/cam4.353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329001/
https://www.ncbi.nlm.nih.gov/pubmed/25417601
http://dx.doi.org/10.1002/cam4.353

Ejemplares similares